



Apriso[®] (mesalamine) – First-time generic

- On November 27, 2019, Mylan launched an [AB-rated](#) generic version of Bausch Health [Apriso \(mesalamine\)](#) 375 mg extended-release capsules.
- Apriso is approved for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
- Mesalamine is also available as branded 250 mg and 500 mg controlled-release capsules ([Pentasa[®]](#)), generic [800 mg delayed-release tablets](#), brand ([Lialda[®]](#)) and generic [1,200 mg delayed-release tablets](#), brand ([Delzicol[®]](#)) and generic [400 mg delayed-release capsules](#), brand ([Rowasa[®]](#)) and generic [rectal enema](#), and brand ([Canasa[®]](#)) and generic [rectal suppository](#).
 - Pentasa is approved for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
 - Mesalamine 800 mg delayed-release tablets are approved for the treatment of moderately active ulcerative colitis in adults.
 - Mesalamine 1,200 mg delayed-release tablets are approved for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
 - Mesalamine 400 mg delayed-release capsules are approved for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older, and for the maintenance of remission of ulcerative colitis in adults.
 - Mesalamine rectal enema and suppository are approved for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.